Skip to content
Hair Pipeline
← Recruiting trials
NCT06924632Phase 3Completed

Efficacy & Safety of Minoxidil SL Tablets in Men With AGA

Phase 3, Multicentre, Randomised, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Minoxidil Sublingual (SL) Tablet (2.5 mg) Twice Daily (BID) in the Treatment of Male Androgenetic Alopecia (AGA) in Adults

In the register

The register attaches this trial to Minoxidil (topical), currently at “Approved” in the register. The programme's phase is checked by hand; the trial's is declared by its sponsor.

What the registry records

Status
Completed
Declared phase
Phase 3
Sponsor
Samson Clinical Operations Pty Ltd
Participants (registry)
142
Start
July 2025
Primary completion
May 2026
Study completion
May 2026
Last registry update
May 2026
Countries
Australia

Conditions studied: Androgenetic Alopecia, Male Pattern Baldness

Interventions: Minoxidil, Placebo

Full record on ClinicalTrials.gov ↗

Other trials of Minoxidil (topical)

  • NCT07529977Phase 3Not yet recruiting

    Phase 3 Study to Evaluate the Efficacy and Safety of Oral Minoxidil (N1087) in Men With Androgenetic Alopecia.

  • NCT07273799Phase 3Not yet recruiting

    Comparison of Outcomes Between Topical Minoxidil Versus Oral Minoxidil for the Treatment of Androgenetic Alopecia

  • NCT07056933Not yet recruiting

    Effect of Minoxidil Solution Iontophoresis on Androgenic Alopecia

  • NCT07012486Early phase 1Recruiting

    Efficacy of Dihydroartemisinin for Treating Female Androgenetic Alopecia

  • NCT07080931Phase 3Recruiting

    Efficacy and Safety of 5% Minoxidil Foam in Female Androgenetic Alopecia

  • NCT07076706Phase 2Completed

    Clinical Trial to Evaluate CG2001 in Chinese Adult Male Participants With Androgenetic Alopecia

  • NCT05888922Phase 3Active, not recruiting

    Evaluation of Efficacy and Safety of Oral Minoxidil 1 mg in Female Androgenetic Alopecia

  • NCT06043349Phase 4Status unknown

    Effectiveness and Safety of Platelet-rich Plasma and Topical 5% Minoxidil Combination in Male Androgenetic Alopecia

  • NCT04721548Phase 3Completed

    Treatment of Androgenetic Alopecia in Men for 24 Weeks

  • NCT05296863Phase 3Completed

    Adipose-derived Stem Cell Conditioned Media as a Novel Approach for Hair Regrowth in Male Androgenetic Alopecia

  • NCT02486848Withdrawn

    Minoxidil Dose Response Study in Females Identified Through IVD Testing as Non-Responders to 5% Topical Minoxidil

  • NCT04090801Phase 4Completed

    Comparison of Topical Minoxidil 5% in Ethanol Plus Propylene Glycol Versus Minoxidil 5% in Ethanol Alone in Treatment of Women With Female Pattern Hair Loss

Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.